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Abstract Anandamide, an endogenous cannabinoid substance, 
is hydrolyzed by an amidohydrolase activity present in rat brain 
and liver. We report that the bromoenol lactone, (E)-6-
(bromomethylene) tetrahydro-3-(l-naphthalenyl)-2H-pyran-2-
one (BTNP), is a potent inhibitor of this enzyme activity. BTNP 
prevented anandamide hydrolysis in rat brain microsomes with 
an IC50 of 0.8 ± 0.3 pM. Kinetic and dialysis experiments 
indicated that this effect was non-competitive and irreversible. 
After Chromatographie fractionation of the enzyme activity, 
BTNP was still effective, suggesting that it interacts directly with 
the enzyme. Anandamide hydrolysis was 12-fold greater in rat 
cortical neurons (1.94 ±0.1 pmol/min/mg protein) than in cortical 
astrocytes (0.16 ±0.01 pmol/min/mg protein) and, in either cell 
type, it was inhibited by BTNP (IC50 = 0.1 uM in neurons). 
These results suggest that BTNP may provide a useful lead for 
the development of novel inhibitors of anandamide hydrolysis. 
© Federation of European Biochemical Societies. 
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1. Introduction 
To ensure that chemical transmission in the nervous system 
occurs with high spatial and temporal resolution, neurotrans-
mitters released into the synaptic cleft are rapidly disposed of 
by a variety of mechanisms of inactivation. These fall into two 
main categories: reuptake into cells mediated by transporter 
proteins terminates the synaptic effects of biogenic amines, 
glutamate and y-aminobutyrate [1,2], while breakdown by ex-
tracellular hydrolyzing enzymes terminates the effects of ace-
tylcholine [3], and participates in the inactivation of many 
neuropeptides [3-5]. Because of these essential regulatory 
functions, neurotransmitter-inactivating processes have pro-
vided targets for drugs of both experimental and clinical sig-
nificance, ranging from amine reuptake blockers to acetylcho-
linesterase inhibitors. 
The abundant expression of cannabinoid receptors in brain 
and the behavioral consequences of their stimulation by drugs 
have led to suggest that an endogenous cannabinoid system 
exists in brain, which may participate in modulating such 
diverse brain functions as cognition, emotion and movement 
[6,7]. Anandamide (A^-arachidonoylethanolamine), a cannabi-
noid receptor agonist isolated from brain tissue, is thought to 
be a central component of this modulatory system [8]. Anan-
damide mimics many of the pharmacological effects of can-
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nabinoid drugs both in vitro and in vivo [8,9], and is produced 
in and released from neurons in an activity-dependent manner 
[10]. Two potential mechanisms of anandamide inactivation 
have been described. An enzyme activity, abundant in brain 
and liver, catalyses the hydrolysis of anandamide to arachi-
donic acid and ethanolamine [11-13]. This amidohydrolase 
activity is enriched in areas of the rat central nervous system 
that contain high densities of cannabinoid receptors, suggest-
ing that it may contribute to anandamide degradation at its 
sites of action [12]. In addition to enzymatic hydrolysis, evi-
dence for the existence of an anandamide transport system 
has been provided in primary cultures of rat brain neurons 
[10]. Do these mechanisms participate in the physiological 
inactivation of anandamide and, if so, what are their relative 
roles? These questions have been difficult to address, partly 
because selective pharmacological blockers of anandamide in-
activation are not yet available. 
In the present study we show that the bromoenol lactone, 
(E)-6-(bromomethylene) tetrahydro-3-(l-naphthalenyl)-2H-
pyran-2-one (BTNP, Fig. 1), a mechanism-based inhibitor of 
Ca2+-independent phospholipase A2 [14], is also potent in 
preventing anandamide hydrolysis both in vitro and in situ. 
Its distinctive chemical structure and pharmacological proper-
ties may make it an interesting lead for the development of 
more potent and selective inhibitors of anandamide hydroly-
sis. 
2. Experimental procedures 
2.1. Materials 
Radiolabeled anandamide (221 Ci/mmol, 8177 GBq/mmol) was 
purchased from New England Nuclear (Wilmington, DE), and 
BTNP from Biomol Inc. (Plymouth Meeting, PA). Arachidonoyltri-
fluoromethylketone (AATFMK) was synthesized as previously de-
scribed [15]. Briefly, arachidonoylchloride (Nu-Chek Prep, Elysian, 
MN) was allowed to react with trifluoroacetic anhydryde in dichloro-
methane containing pyridine for 1 h at room temperature. After ex-
traction with chloroform, identity and purity of the reaction product 
were confirmed by gas-chromatography/mass spectrometry. 
2.2. Anandamide amidohydrolase assays 
Microsome fractions were prepared from brain or liver tissues of 
Wistar rats, as previously described [12]. Standard anandamide ami-
dohydrolase assays were carried out for 10 min at 37°C in 0.5 ml of 
Tris-HCl buffer (50 mM, pH 8) containing microsomes (0.2 mg of 
protein) and [3H]anandamide (1 nM [3H]anandamide brought to 100 
nM with unlabeled anandamide). The reactions were stopped by add-
ing 1 ml of cold methanol, followed by extraction with 2 ml of chloro-
form. The chloroform phases were dried under a stream of nitrogen 
and fractionated by silica gel G thin-layer chromatography (TLC) 
(Analtech, Newark, DE), using a solvent system of chloroform/meth-
anol/ammonium hydroxide (90:10:1, v/v/v). The lipids were visualized 
by spraying the TLC plates with a solution of phosphomolybdic acid 
in ethanol (10%, w/v). The bands comigrating with authentic free 
arachidonic acid (AA) were scraped off the plates, and radioactivity 
measured by liquid scintillation counting. BTNP and AATFMK were 
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diluted, from a stock solution of 100 mM in DMSO, with Tris-HCl 
buffer (50 mM) to a working solution (430 |lM), which was used for 
subsequent serial dilutions. Samples were incubated with the drugs for 
10 min at 37°C prior to the enzyme assay. 
2.3. Amidohydrolase fractionation by Fast Protein Liquid 
Chromatography (FPLC) 
Samples of brain or liver microsome fractions (1 mg of protein) 
were applied, at a flow rate of 2 ml/min, to a MonoQ HR 10/10 
column (Pharmacia, Piscataway, NJ), which had been equilibrated 
with Tris-HCl (20 mM, pH 8) containing NaCl (50 mM). Ananda-
mide amidohydrolase activity was eluted from the column with a 
gradient of NaCl in Tris-HCl (20 mM), as illustrated in Fig. 3. The 
column effluent was collected in 2-ml fractions, 0.5 ml of which were 
used for the enzyme assays. 
2.4. Preparation of neuron and astrocyte cultures 
Cortical neurons devoid of glial cells were prepared in a serum-free 
culture medium, essentially as previously described [16]. Briefly, cere-
bral cortices of 18-day-old Wistar rat embryos were dissected, cells 
were dissociated mechanically and seeded at a density of 106 cells/ml 
in culture dishes which had been previously coated with polyornithine 
(10 ug/ml) and polylysine (100 ug/ml). The culture medium was com-
posed of Dulbecco's modified Eagle's medium (DMEM) supple-
mented with streptomycin (100 ug/ml), penicillin (60 ug/ml), insulin 
(25 u.g/ml), transferrin (100 u.g/ml), putrescine (60 U.M), progesterone 
(20 nM), sodium selenite (30 nM), NaHC0 3 (10 mM) and HEPES (10 
mM, pH 7.3). 
Cortical astrocytes were prepared from 18-day-old Wistar rat em-
bryos. Cerebral cortices were dissected and cells were mechanically 
dissociated in an Earle's balanced salt solution containing bovine 
serum albumin (BSA, 0.2%), trypsin inhibitor (0.2%), and DNAse 
(50 Kunitz units/ml). Cells were plated at a concentration of 
25X106 cells per dish (90 mm diameter) using a culture medium 
composed of a Minimum Essential Medium (44%), F-12 nutrient 
mixture (44%), glucose (0.6%), fetal bovine serum (5%), fetal horse 
serum (5%), glutamine (1 mM) and phenol red (0.0015%). Cells were 
replated twice, after 1 and 2 weeks in culture, and grown in a medium 
in which fetal horse serum had been replaced by fetal bovine serum. 
2.5. Anandamide amidohydrolase activity in neurons and astrocytes in 
culture 
Enzyme assays were carried out with neurons after 5 to 6 days in 
culture, and with astrocytes after 3 to 4 weeks in culture. Cells were 
rinsed twice with Krebs-Tris buffer (NaCl 136 mM, KC1 5 mM, 
MgCl2 1.2 mM, CaCl2 2.5 mM, glucose 10 mM, Trizma base 20 
mM; pH 7.4). [3H]Anandamide (0.45 nM) was dissolved in Krebs-
Tris buffer and mixed with unlabeled anandamide to reach a final 
concentration of 100 nM. When testing the effects of BTNP, cells 
were preincubated for 10 min with the drug (0.018-10 |iM). The 
same concentration of BTNP was also added during the incubation 
period. After 20 min of incubation at 37°C, the medium was removed 
and the cells were rinsed with Krebs-Tris buffer containing fatty acid-
free BSA (0.1%). The cells were collected in an ice-cold mixture of 
Krebs-Tris buffer/methanol (5:2; v/v), and lipids were extracted by 
adding chloroform to reach a final ratio of buffer/methanol/chloro-
form of 5:2:3 (v/v/v). The chloroform phases were split into two equal 
samples. One was used for phospholipid analysis, which was car-
ried out on plastic-backed TLC plates (Alltech, Deerfield, IL) by 
using a solvent system of chloroform/methanol/ammonia/water 
(65:25:2.7:0.7; v/v/v). The second was used for anandamide analysis, 
which was carried out by open-bed column chromatography followed 
by TLC using a solvent system of chloroform/methanol/ammonia 
(80:20:1; v/v/v). In either case, bands from the plastic-backed TLC 
plates were cut at 1-cm intervals, and radioactivity measured by liquid 
scintillation counting. 
2.6. Anandamide amidohydrolase activity in neuron and astrocyte 
homogenates 
Neurons and astrocytes were grown in culture as described above. 
The cells were incubated twice at 37°C for 10 min with HEPES buffer 
(pH 7.4), lysed by adding ice-cold Tris-HCl (50 mM, pH 8), and 
homogenized. Anandamide amidohydrolase activity was measured 
under standard conditions. 
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3. Results and discussion 
We incubated rat brain microsomes with exogenous 
[3H]anandamide (100 nM) for 10 min, purified by T L C the 
free [3H]arachidonic acid produced during the incubations, 
and quantified it by liquid scintillation counting. At this sub-
strate concentration, chosen to approximate physiological 
conditions and well below the enzyme Km [12], anandamide 
amidohydrolase activity was on average 2.85 ± 0.13 pmol/min/ 
mg of protein (mean ± SEM, n = 34). When we included 
B T N P (20 uM) in the incubation buffer, the radioactivity 
associated with arachidonic acid was reduced to background 
levels, indicating a complete inhibition of the enzyme activity 
(data not shown). Fig. 2A demonstrates that this inhibitory 
effect was concentration-dependent: in three experiments the 
median inhibitory concentration (IC50) of B T N P was 0.8 ± 0.3 
U.M. 
Such potent inhibition of anandamide amidohydrolase ac-
tivity was reminiscent of that produced by B T N P on cytosolic 
Ca 2 +- independent phospholipase A 2 activity, which was inac-
tivated with an IC 5 0 of approximately 0.1 (0.M [14]. Inhibition 
of this phospholipase by B T N P was thought to result from 
the covalent binding of the drug at or near the enzyme's active 
site [14]. To examine the mechanism of anandamide amidohy-
drolase inhibition by BTNP, we incubated rat brain micro-
somes with a maximally effective concentration of the drug 
(25 n M ) in the presence of varying concentrations of 
[3H]anandamide (from 12.5 to 200 uM). Lineweaver-Burk 
analysis of the results, illustrated in Fig. 2B, showed that 
the inhibitory effect of B T N P was non-competitive, as ex-
pected of an irreversible enzyme inhibitor. In the absence of 
BTNP, we obtained a Km for anandamide of 33 ± 5.6 [iM and 
a I'max of 2038 ± 302 pmol/min/mg of protein (n = 3). In the 
presence of B T N P (25 uM), we obtained a Km of 39 ± 11 u M 
and a Vmax of 149 ± 4 9 pmol/min/mg of protein (« = 3). 
In further support of an irreversible mechanism, we noted 
that extensive dialysis of the microsomal incubates (1 1/ml 
of sample for 4 h) did not reverse the B T N P inhibition 
(Table 1). 
There is both experimental and therapeutic interest in de-
veloping potent and selective inhibitors of anandamide hy-
drolysis. This has recently led to identify a group of polyun-
saturated fatty acyl trifluoromethylketones which may act as 
Fig. 1. Chemical structure of (E)-6-(bromomethylene) tetrahydro-3-
(l-naphthalenyl)-2H-pyran-2-one (BTNP). 
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Fig. 2. Inhibition of [3H]anandamide hydrolysis in rat brain microsomes. A: Concentration-dependent inhibition with BTNP and arachidonoyl-
trifluoromethylketone (AATFMK). Results are from three experiments. B: Lineweaver-Burk analysis of BTNP inhibition. Results are from one 
experiment representative of three. 
transition-state inhibitors of this enzyme activity [17]. One 
such compound, A A T F M K , prevents anandamide hydrolysis 
in subcellular fractions of neuroblastoma N18TG2 cells, 
where it displays an IC 5 0 of 0.7-3 u M [18]. Under our exper-
imental conditions, A A T F M K effectively inhibited ananda-
mide amidohydrolase activity, al though 5-fold less potently 
than B T N P ( I C 5 0 = 4 ± 1 uM, n = 3) (Fig. 2A). 
To obtain evidence that B T N P acts through a direct inter-
action with the enzyme responsible for anandamide hydroly-
sis, we examined the inhibitory effects of this drug after frac-
tionation of the enzyme activity by F P L C . In three 
experiments, we applied samples of non-solubilized rat brain 
microsomes to a M o n o Q column, eluted the proteins with a 
NaCl gradient, and measured anandamide amidohydrolase 
activity in the column eluate. As shown by the representative 
experiment depicted in Fig. 3, four peaks of enzyme activity 
were resolved by M o n o Q chromatography (lower tracing, 
control), which were all effectively inhibited by B T N P (10 
uM) (lower tracing, BTNP). Multiple peaks of anandamide 
amidohydrolase activity have been already observed after par-
tial purification from pig brain microsomes, but the signifi-
cance of these putative isoforms is still unknown [19]. The 
recent cloning of an hydrolase involved in the degradation 
of long-chain fatty acid amides, including anandamide, should 
help shed light on this question [20]. 
In the rat, anandamide amidohydrolase activity is mainly 
localized in liver and brain [12]. When tested on crude micro-
somes prepared from rat liver tissue, B T N P inhibited ananda-
mide hydrolysis with an IC50 that was about 100-fold greater 
than that measured in brain microsomes (79.5 ±12 .9 u M , 
n = 3). However, this marked difference likely resulted from 
B T N P degradation by liver enzymes, rather than from the 
existence of tissue-specific amidohydrolase isoenzymes. Two 
findings support such conclusion. First, after F P L C fractiona-
tion, anandamide amidohydrolase activity from liver was in-
hibited by B T N P as effectively as the activity from brain (data 
not shown). Second, incubation of B T N P with a mixture of 
brain and liver microsomes for 10 min at 37°C prevented the 
inhibition of anandamide hydrolysis (data not shown). 
The regional distribution of anandamide hydrolysis in the 
rat central nervous system, paralleling that of CBi cannabi-
noid receptors, suggests that this enzymatic reaction may be at 
least in part responsible for the biological disposition of anan-
damide [12]. Yet, it is still unclear whether anandamide ami-
dohydrolase activity is localized in neurons (which are 
thought to express the majority of brain CBi receptors) 
[21,22], in glial cells or in both. We prepared cell-type specific 
cultures of neurons or astrocytes from the cortex of embry-
onic rats, and measured anandamide amidohydrolase activity 
in homogenates of these cultures. Supporting a preferential 
neuronal localization, we found that the enzyme activity was 
12-fold greater in neurons (1.94 ± 0 . 1 pmol/min/mg protein, 
n = l) than in astrocytes (0.16 ±0.01 pmol/min/mg protein, 
n - 6). B T N P was equally potent in inhibiting anandamide 
amidohydrolase activity, producing in either cell type an in-
hibition of approximately 80% at 0.5 |xM (neurons: control 
9472 ± 4 6 6 dpm/min/mg of protein; B T N P treated 1807 ± 7 8 
dpm/min/mg of protein, w = 4; astrocytes: control 9 1 9 ± 1 7 
dpm/min/mg of protein; B T N P treated 197 ± 2 1 dpm/min/ 
mg of protein, n = 3. Da ta are from one experiment represen-
tative of three). Noteworthy, Shivachar and coworkers have 
previously reported that cultures of rat cortical astrocytes 
contain negligible levels of anandamide amidohydrolase activ-
ity [23]. This discrepancy may be due to different culture con-
ditions and/or assay sensitivity. 
To determine whether B T N P inhibits anandamide hydrol-
ysis in intact cells, we tested its effects on primary cultures of 
rat cortical neurons, incubated for 4 min in a medium con-
taining [3H]anandamide. As previously noted, [3H]anand-
amide was readily hydrolyzed by the neurons, and virtually 
all of the [3H]arachidonate produced in this reaction was 
found esterified into cellular phospholipids, most prominently 
into phosphatidylcholine (PC) and phosphatidylethanolamine 
(PE) [10]. B T N P prevented [3H]anandamide hydrolysis by the 
Table 1 
Microsomes Microsomes+10 uM BNTP 
(dpm/min/mg protein ± SEM) 
(li = 3) 
(dpm/min/mg protein ± SEM) 
(n = 3) 
Before dialysis 
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Fig. 3. Fractionation of anandamide amidohydrolase activity by 
MonoQ column chromatography. Proteins were eluted with a NaCl 
gradient, as illustrated in the upper tracing, and elution was moni-
tored by UV detection (A2so, middle tracing). Fractions of the col-
umn eluate were collected and assayed for enzyme activity under 
standard conditions with or without BTNP (10 uM) (lower trac-
ings). Results are from one experiment, representative of three. 
neurons in a concentration-dependent manner, as indicated by 
a reduced incorporation of [3H]arachidonate into PC and PE, 
as well as by an increased intracellular accumulation of un-
metabolized [3H]anandamide. Both effects occurred with an 
IC5o close to 0.1 u,M (Fig. 4). 
We have also investigated the effects of BTNP on the en-
zymes involved in anandamide biosynthesis. In mixed cortical 
cultures, formation of anandamide and other 7V-acylethanol-
amines is thought to be mediated by a D-type phospholipase 
activity, and is stimulated by the Ca2+ ionophore ionomycin 
[10,24,25]. To determine whether BTNP inhibits JV-acyletha-
nolamine formation we labeled cortical cultures overnight 
with [3H]ethanolamine, and stimulated them with ionomycin 
(1 N,M) either in the presence or in the absence of BTNP (25 
uM). Radioactivity in the TV-acylethanolamine fractions, de-
termined after TLC fractionation, was: control 83 ±41 dpm, 
ionomycin 123 ±9 dpm, ionomycin plus BTNP 248 ± 35 dpm 
(n = 3). These results suggest that BTNP inhibits anandamide 
degradation without affecting the formation of anandamide 
and other JV-acylethanolamines [10]. Next, we measured the 
effects of BTNP on the biosynthesis of 7V-arachidoyl PE, a 
putative anadamide precursor. Particulate fraction of the rat 
brain tissue were incubated at 37°C for 60 min in the presence 
of di[14C]arachidonoyl phosphatidylethanolamine and the N-
arachidonoyl PE produced was fractionated by TLC. Under 
these conditions, BTNP inhibited A^-arachidonoyl PE with an 
IC50 of approximately 2 u.M [24]. 
4. Conclusion 
Our results indicate that BTNP is a potent and irreversible 
inhibitor of anandamide hydrolysis. BTNP was previously 
shown to inhibit chymotrypsin-like proteases and, very po-
tently, cytosolic Ca2+-independent phospholipase A2. Despite 
this relative lack of selectivity, the potency of BTNP in inhib-
iting anandamide hydrolysis, its efficacy both in vitro and in 
situ, and its distinctive chemical structure — different from 
previously described amidohydrolase inhibitors — suggest 
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Fig. 4. Inhibition of [3H]anandamide hydrolysis by BTNP in neu-
rons. Cultures of rat cortical neurons were incubated in a medium 
containing [3H]anandamide with or without BTNP. [3H]anand-
amide, [3H]phosphatidylethanolamine (PE) and [3H]phosphatidyl-
choline (PC) were purified and quantified by liquid scintillation 
counting. Points represent the mean ± SEM of 3-6 independent de-
terminations. 
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that this drug may provide a useful lead for the development 
of novel pharmacological agents that interfere with ananda-
mide inactivation. Such drugs may help elucidate the roles of 
the endogenous cannabinoid system, and may find applica-
tions in pathological conditions where an indirect activation 
of this system is expected to cause a desirable pharmacological 
effect. 
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